- Previous Close
0.0155 - Open
0.0237 - Bid 0.0110 x --
- Ask 0.0220 x --
- Day's Range
0.0155 - 0.0237 - 52 Week Range
0.0082 - 0.0470 - Volume
50,100 - Avg. Volume
24,537 - Market Cap (intraday)
5.759M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
filament.health--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: FLHLF
View MorePerformance Overview: FLHLF
Trailing total returns as of 4/6/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FLHLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FLHLF
View MoreValuation Measures
Market Cap
2.79M
Enterprise Value
2.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.31
Price/Book (mrq)
3.29
Enterprise Value/Revenue
1.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--